Thursday, April 24, 2014 10:49:17 AM
It seems clear they have "data" and will be presenting it, in the abstract or poster or both. Through two dose levels for all 36 patients (it appears all are enrolled, with the further 24 under enrollment by now), and through three dose levels by 5/19 (the data from which seems open for discussion at ASCO, and by PR to the public). This should clearly include efficacy data. She stated: "we have filled the first two dose levels with patients," (see my last post) meaning at least 36 patients have by the time of the abstract submission received two dose levels. Their site states:
[brackets and emphasis mine]
Although the focus of the Phase II stage will be on efficacy, it does not mean they aren't viewing efficacy and tabulating results thus in the Ph I stage. How else can you find optimal dose finding without efficacy results?
And so, it seems to me they will have safety/tolerability, dose finding and initial efficacy (localized and it seems, systemic) data to share at ASCO, both in the abstract, and especially poster. Then, by PR (which should be even more complete/ current, and might possibly include other mentions such as Breakthrough Therapy designation, etc.), we will immediately after be informed of the complete, up-to-date picture of things, and that, combined with what they have displayed at ASCO, will be open to talks at their large booth space, on Monday, June 2nd and Tuesday, June 3rd (as longusa pointed out).
Recent NWBO News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM